Oisin Biotechnologies, Inc.
Senolytic drug platform targeting cellular senescence to extend healthspan
- Sector
- Biotech
- Headquarters
- SEATTLE, WA
- Latest Form D
- $5.4M, Jul 2024
- Total capital
- $10.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $10.9M
- 4 Form D · last Jul 2024
- 27 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 16 pending · first 2022
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$5.4M
- Private capital raisedForm D · SEC · 3rd filing$475K
- Private capital raisedForm D · SEC · 2nd filing$2.1M
- Private capital raisedForm D · SEC · 1st filing$3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Danjuma QuarlessDirectorNamed in SEC Form D filings
- David GobelDirectorNamed in SEC Form D filings
- Eric GarciaExecutive OfficerNamed in SEC Form D filings
- Gary HudsonExecutive Officer, DirectorNamed in SEC Form D filings
- John LewisExecutive OfficerNamed in SEC Form D filings
- Matthew ScholzExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- Stephen HilbertExecutive OfficerNamed in SEC Form D filings
- Steve HilbertExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 18- PendingCompositions, Systems, And Methods For Reducing Adipose TissueUSPTOApplication 19281400
- PendingFusogenic Lipid Nanoparticles And Methods For The Manufacture And Use Thereof For The Target Cell-specific Production Of A Therapeutic Protein And For The Treatment Of A DiseaseUSPTOApplication 19025917
- PendingSystems And Methods For The Targeted Production Of A Therapeutic Protein Within A Target CellUSPTOApplication 18444265
Show all 18 patent records
- Compositions, Systems, And Methods For Reducing Adipose TissueApr 23, 2026 · Application 19281400Pending
- Fusogenic Lipid Nanoparticles And Methods For The Manufacture And Use Thereof For The Target Cell-specific Production Of A Therapeutic Protein And For The Treatment Of A DiseaseNov 13, 2025 · Application 19025917Pending
- Systems And Methods For The Targeted Production Of A Therapeutic Protein Within A Target CellNov 21, 2024 · Application 18444265Pending
- Compositions And Methods For Liver-specific Expression Of FollistatinNov 14, 2024 · Application 18620618Pending
- Fusogenic Lipid Nanoparticles For Target Cell-specific Production Of A Therapeutic Protein Fusogenic Lipid Nanoparticles And Methods Of Manufacture And Use Thereof For The Target Cell-specific Production Of A Therapeutic Protein And For The Treatment Of A DiseaseNov 2, 2023 · Application 18060292Pending
- Fusogenic Lipid Nanoparticles And Methods For The Manufacture And Use Thereof For The Target Cell-specific Production Of A Therapeutic Protein And For The Treatment Of A Disease, Condition, Or Disorder Associated With A Target CellJul 13, 2023 · Application 17983167Pending
- Fusogenic Lipid Nanoparticles For Target Cell-specific Production Of A Therapeutic ProteinMar 14, 2023 · US 11,603,543Granted
- Expression Constructs, Fusogenic Lipid-based Nanoparticles, And Methods Of Use ThereofDec 13, 2022 · US 11,525,146Granted
- Fusogenic Lipid Nanoparticles For The Target Cell-specific Production Of Rapamycin Inducible Therapeutic ProteinsApr 7, 2022 · Application 17393313Pending
- Expression Constructs And Systems For Systemic And Non-specific In Vivo Delivery Of A Nucleic Acid To Human Cells And Transient Target Cell-specific Production Of A Therapeutic ProteinJan 9, 2020 · Application 16583197Pending
- Systems And Methods For The Targeted Production Of A Therapeutic Protein Within A Target CellJan 14, 2016 · Application 14862161Pending
- Compositions, Systems, And Methods For Reducing Adipose TissueApplication 63441611Pending
- Compositions And Methods For Liver-specific Expression Of FollistatinApplication PCTUS2022045468Pending
- Fusogenic Lipid Nanoparticles And Methods For The Manufacture And Use Thereof For The Target Cell-specific Production Of A Therapeutic Protein And For The Treatment Of A Disease, Condition, Or Disorder Associated With A Target CellApplication PCTUS2019028207Pending
- Fusogenic Lipid Nanoparticles And Methods For The Manufacture And Use Thereof For The Target Cell-specific Production Of A Therapeutic Protein And For The Treatment Of A Disease, Condition, Or Disorder Associated With A Target CellApplication 62821084Pending
- Fusogenic Lipid Nanoparticles For The Target Cell-specific Production Of Rapamycin Inducible Therapeutic ProteinsApplication 62801072Pending
- Compositions, Systems, And Methods For Reducing Adipose TissueApplication PCTUS2024013231Pending
- Fusogenic Lipid Nanoparticles For The Target Cell-specific Production Of Rapamycin Inducible Therapeutic ProteinsApplication PCTUS2020016679Pending
Related companies, and why
- Scienture Holdings, Inc.Similar federal contract value in Biotech · null in contracts
- Aloe Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- MYOGENICA INC.Similar federal contract value in Biotech · null in contracts
- Inozyme PharmaSimilar federal contract value in Biotech · null in contracts
- Encepheal Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- PELICAN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .